Company Filing History:
1 out of 10 
1 out of 1 
1 out of 45 
Years Active: 2016
Title: Innovations in Medical Treatment: The Contributions of Antonio Dávalos Errando
Introduction: Antonio Dávalos Errando, an inventive mind hailing from Girona, Spain, is known for his significant contribution to medical advancements through his patented invention. His work focuses on developing treatments for critical health issues, particularly neurological disorders.
Latest Patents: Dávalos Errando holds a notable patent titled "Apotransferrin for the treatment of brain stroke." This invention involves the innovative use of apotransferrin in the preparation of a medicament aimed at treating brain strokes. The drug formulated with apotransferrin is designed for administration via vascular routes, with a preference for intravenous or intraarterial delivery. This approach represents a promising avenue for addressing the urgent medical needs associated with brain strokes.
Career Highlights: Throughout his career, Antonio Dávalos Errando has been associated with reputable research institutions, notably the Fundació Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol and the Instituto de Investigación Sanitaria—Fundación para la Investigación del Hospital La Fe. His experiences in these esteemed organizations have contributed to his expertise in medical research and innovation.
Collaborations: Dávalos Errando has collaborated with several distinguished colleagues, including Teresa Gasull Dalmau and Núria Degregorio-Rocasolano Barbany. Their joint efforts highlight the importance of teamwork in advancing medical research and developing effective treatments.
Conclusion: Antonio Dávalos Errando's innovative work in the field of medicine underscores the vital role of inventors in addressing complex health challenges. His patent for apotransferrin illustrates a promising treatment for brain stroke, showcasing the potential for future advancements in medical therapies. As research continues, the impact of his contributions will likely resonate in the medical community for years to come.